Meeting
2023 ASCO Genitourinary Cancers Symposium
Overall survival, efficacy, and safety outcomes beyond front-line modern therapies in metastatic clear-cell renal cell carcinoma.
Authors
Jordyn Kreutzfeldt
University of Arizona Internal Medicine Residency Program, Tucson, AZ
Mavis Obeng-Kusi , Ricardo J. Estrada-Mendizabal , Briana M Choi , Ivo Abraham , Alejandro Recio-Boiles , Jordyn Kreutzfeldt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 667)
DOI
10.1200/JCO.2023.41.6_suppl.667
Abstract #
667
Poster Bd #
G18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2021 Gastrointestinal Cancers Symposium
Trifluridine/tipiracil outcomes in third- or later lines versus placebo in metastatic gastric cancer treatment: An exploratory subgroup analyses from the TAGS study.
First Author: Josep Tabernero
Poster
2019 Genitourinary Cancers Symposium
Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
First Author: Amishi Yogesh Shah